bioAffinity stock soars after receiving patent allowance for AI lung cancer test
PositiveFinancial Markets

bioAffinity's stock has surged following the announcement of a patent allowance for its innovative AI-driven lung cancer test. This development is significant as it not only highlights the company's advancements in cancer diagnostics but also positions bioAffinity as a key player in the biotechnology sector. Investors are optimistic about the potential impact of this technology on early cancer detection, which could lead to better patient outcomes and increased market share for the company.
— Curated by the World Pulse Now AI Editorial System